Literature DB >> 30757919

The use of bevacizumab in pediatric retinal and choroidal disease: A review.

Peter J Belin1, Andrew C Lee1, Giovanni Greaves1, Jennifer Kosoy2, Ronni M Lieberman3.   

Abstract

The use of intravitreal bevacizumab in pediatric retinal and uveitic disease has become more widespread over the past decade. This article serves to outline the rationale underlying the use of intravitreal bevacizumab, and which disease entities it should be appropriately thought of as a primary or solo therapy, as opposed to an adjuvant one. Also presented is the relevant literature regarding each of these retinopathies.

Entities:  

Keywords:  Bevacizumab; Coats’ disease; choroidal neovascularization; familial exudative vitreoretinopathy; retinopathy of prematurity; sickle cell retinopathy

Mesh:

Substances:

Year:  2019        PMID: 30757919     DOI: 10.1177/1120672119827773

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  3 in total

1.  Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center.

Authors:  Carol L Shields; Sanika Udyaver; Lauren A Dalvin; Li-Anne S Lim; Hatice T Atalay; Chloe T L Khoo; Mehdi Mazloumi; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2019-06       Impact factor: 1.848

2.  Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab.

Authors:  Ameay V Naravane; Peter J Belin; Shaina Rubino; Polly A Quiram
Journal:  Front Pediatr       Date:  2022-02-11       Impact factor: 3.418

Review 3.  Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer.

Authors:  Koichi Furukawa; Tatsuya Nagano; Motoko Tachihara; Masatsugu Yamamoto; Yoshihiro Nishimura
Journal:  Molecules       Date:  2020-08-26       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.